Current Edition

antibody drug conjugates

ASH: Roche’s Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing data

The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up …

Continue Reading →
ASH 2021

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gilead …

Continue Reading →